Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

被引：0
|
作者：
Rajeev Dhere
Vistasp Sethna
Hitesh Malviya
Rajeshwari Adhiseshan
机构：
[1] Serum Institute of India Private Limited,
来源：
Infectious Diseases and Therapy | 2022年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1297 / 1299
页数：2
相关论文
共 50 条
  • [41] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    VACCINE, 2010, 28 (48) : 7634 - 7643
  • [42] COST-EFFECTIVENESS OF SWITCHING FROM THE 10-VALENT TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWEDEN
    Wasserman, M.
    Dorange, A. C.
    Palmborg, A.
    McDade, C.
    Wilson, M.
    Horn, E.
    VALUE IN HEALTH, 2022, 25 (01) : S110 - S110
  • [43] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [44] COST-EFFECTIVENESS ANALYSIS OF THE PEDIATRIC 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE COMPARED TO LOWER-VALENT ALTERNATIVES IN ARGENTINA
    Ta, A.
    Mac Mullen, M.
    Freigofaite, D.
    Huang, L.
    Waren, S.
    Carballo, C.
    Rey-Ares, L.
    VALUE IN HEALTH, 2023, 26 (12) : S199 - S199
  • [45] COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
    Claes, C.
    Mittendorf, T.
    Kuchenbecker, U.
    Rose, M.
    Reinert, R. R.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [46] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
    Ansaldi, Filippo
    Pugh, Sarah
    Amicizia, Daniela
    Di Virgilio, Roberto
    Trucchi, Cecilia
    Orsi, Andrea
    Zollo, Alessandro
    Icardi, Giancarlo
    PATHOGENS, 2020, 9 (02):
  • [47] Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina
    Rey-Ares, Lucila
    Ta, An
    Freigofaite, Donata
    Warren, Sophie
    Mac Mullen, Mercedes
    Carballo, Carolina
    Huang, Liping
    VACCINE, 2024, 42 (23)
  • [48] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [49] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
    Warren, Sophie
    Barmpouni, Myrto
    Kossyvaki, Vasiliki
    Gourzoulidis, George
    Perdrizet, Johnna
    VACCINES, 2023, 11 (08)
  • [50] Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
    Zhou, Hua
    He, Jinchun
    Wu, Bin
    Che, Datian
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (06) : 1444 - 1452
12345